Comparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome

Title
Comparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome
Author(s)
김영조이민구[이민구]정명호[정명호]안영근[안영근]조정관[조정관]박종천[박종천]강정채[강정채]채성철[채성철]허승호[허승호]홍택종[홍택종]성인환[성인환]채제건[채제건]류재영[류재영]채인호[채인호]조명찬[조명찬]배장호[배장호]라승운[라승운]김종진[김종진]최동훈[최동훈]장양수[장양수]윤정한[윤정한]정욱성[정욱성]승기배[승기배]박승정[박승정]
Keywords
CORONARY-ARTERY-DISEASE; BARE-METAL STENTS; RANDOMIZED-TRIALS; BALLOON ANGIOPLASTY; UNCOATED STENTS; METAANALYSIS; RISK; INTERVENTION; IMPLANTATION; EFFICACY
Issue Date
201109
Publisher
JAPANESE CIRCULATION SOC
Citation
CIRCULATION JOURNAL, v.75, no.9, pp.2120 - 2127
Abstract
Background: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS). Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005-December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (all-cause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448). Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR. (Circ J 2011; 75: 2120-2127)
URI
http://hdl.handle.net/YU.REPOSITORY/24572http://dx.doi.org/10.1253/circj.CJ-11-0263
ISSN
1346-9843
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE